VX-950: Phase Ia data

In a European Phase Ia trial in 35 healthy volunteers, single doses of 25 to 1250 mg of VX-950 were well-tolerated. VRTX said it will begin a multi-dose, placebo-controlled Phase 1b trial in healthy v...